Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
Althoff K, Schlueter D, Anton-Culver H, Cherry J, Denny J, Thomsen I, Karlson E, Havers F, Cicek M, Thibodeau S, Pinto L, Lowy D, Malin B, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Roman A, Sharpless N, Gebo K, Schully S. Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020. Clinical Infectious Diseases 2021, 74: 584-590. PMID: 34128970, PMCID: PMC8384413, DOI: 10.1093/cid/ciab519.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayBlood specimensSARS-CoV-2 enzyme-linked immunosorbent assaySARS-CoV-2 immunoglobulin G (IgG) antibodiesSARS-CoV-2 antibodiesIgG enzyme-linked immunosorbent assayConfidence intervalsImmunoglobulin G antibodiesSARS-CoV-2Sequential testing algorithmEUROIMMUN assaysSymptomatic patientsTesting algorithmStudy visitG antibodiesCommunity transmissionTravel historyStudy participantsUS epidemicEarly weeksImmunosorbent assayTesting capacityAntibodiesWeeksUS states
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply